Verastem Oncology to Participate in Upcoming September Investor Conferences

About this update from Verastem, Inc.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21 st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com . A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI ® FAKZYNJA ® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn . View source version on businesswire.com: https://www.businesswire.com/news/home/20260902001050/en/

View stock analysis, news, and events for Verastem, Inc.